Bruker Corporation announced that it has secured a $25 million order book from three leading European research institutions: ENS‑PSL in Paris, the Max Planck Institute for Solid‑State Research in Stuttgart, and the Institut Européen de Chimie et Biologie in Bordeaux. The orders include a 1 GHz NMR relaxometry system for ENS‑PSL, an 800 MHz and 100 MHz NMR suite plus an E580 FT/CW EPR spectrometer for the Max Planck Institute, and a 1 GHz NMR system for the Bordeaux platform.
The $25 million in new orders represents a 0.7% increase in Bruker’s annual revenue, which was $3.37 billion in FY 2024. Revenue from these contracts will be recognized over fiscal 2026 and 2027, providing a steady, long‑term cash flow that complements Bruker’s existing product mix and supports its cost‑saving initiatives under the “Project Accelerate” transformation strategy.
These high‑field NMR and EPR systems are critical for cutting‑edge research in protein dynamics, battery materials, and disease biology. By delivering advanced instrumentation to these institutions, Bruker strengthens its position as a leader in scientific instrumentation and expands its customer base in academia and industrial research, aligning with the company’s mission to enable breakthrough discoveries.
Bruker’s recent financial performance has shown a slight slowdown, with Q3 2025 revenue down 0.5% year‑over‑year and an organic decline of 4.5%. The new orders therefore provide a meaningful boost to the high‑field segment, offsetting broader market headwinds and reinforcing confidence in the company’s growth trajectory. CEO Frank H. Laukien noted that the contracts “align with Bruker’s strategy to deliver advanced tools to critical research areas and support our long‑term growth plan.”
Overall, the $25 million order book adds a reliable revenue stream for the next two fiscal years, enhances Bruker’s competitive moat in high‑performance magnetic resonance, and signals continued demand for its flagship products amid a challenging macro environment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.